Re­gen­eron wins EU ap­proval for lym­phoma bis­pe­cif­ic fol­low­ing FDA re­jec­tion

EU reg­u­la­to­ry au­thor­i­ties grant­ed con­di­tion­al ap­proval to Re­gen­eron’s bis­pe­cif­ic an­ti­body odronex­tam­ab for two forms of lym­phoma.

It’s Re­gen­eron’s first bis­pe­cif­ic an­ti­body ap­proval in the world …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER